Aim There is a paucity of data on the clinical presentation and management of cancer
patients with acquired haemophilia (AH), we here report a systematic literature review on …

Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies
inhibiting the function of coagulation factor VIII. It is characterized by spontaneous bleeding …

To conduct a systematic review of the literature reporting efficacy and safety of recombinant
factor VIIa (rFVIIa) for the treatment of bleeding in acquired haemophilia and, if data …

Diagnostic delay in acquired haemophilia: Analysis of causes and consequences in a 20-year
Spanish cohort. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe …

The article discusses on the rare bleeding disorder acquired haemophilia A (AHA). The
diagnosis of the disease confirms the inhibitory antibodies and low factor VIII activity …

Mycophenolate mofetil as adjunctive therapy in acquired haemophilia A. - Abstract - Europe
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …

The ability to monitor Factor VIII (FVIII) and Factor IX (FIX) levels is integral to the clinical
management of hemophilia A and B patients, respectively. Factor activity levels are checked …

In acquired haemophilia A (AHA), risk for recurrent bleeding exists until the inhibitor is
detectable. Thus, patients with persisting inhibitor may benefit from prophylaxis with …

ABSTRACT Acquired Hemophilia A (AHA) is a bleeding diathesis related to the
development of factor VIII inhibitor, which can frequently go undetected. It commonly …

Acquired hemophilia A (AHA) is a rare disease that requires urgent management. Currently,
there is no consensus regarding optimal management in aged people. This systematic …